FDA Launches New Webpage for CDER Scientific Review Documents Supporting EUAs for COVID-19 Products – Drug Information Update

If your email program has trouble displaying this email, view it as a web page. FDA Launches New Webpage for CDER Scientific Review Documents Supporting Emergency Use Authorizations for Drug and Biological Therapeutic Products for COVID-19 To promote public confidence in FDA's scientific review process and in ultimately appropriately using products authorized for emergency use, CDER launched a new webpage to disclose information from our scientific review documents supporting Emergency Use Authorizations (EUA) for drug and biological therapeutic products. This new webpage compiles all the scientific review documents supporting EUAs for COVID-19 drug and biological therapeutic products into one location to make documents easier to find. View Webpage This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA